Abstract:Background Checkpoint blockade immunotherapy has dramatically changed cancer treatment; however, these therapies depend on the presence of a pre-existing immune infiltrate. Unfortunately, some patients have few to no infiltrating immune cells, highlighting the need for therapies that can generate antigenic stimuli. Oncolytic viruses, which infect and lyse tumor cells while leaving healthy tissue unharmed, are an attractive means to provide these signals, although the mechanisms of action of these engineered viral therapies remain incompletely understood. Virally induced immunogenic death causes an influx of tumor- and virus- specific effector CD8+ T cells. Many oncolytic viruses also decrease tumor-infiltrating suppressive immune populations, such as regulatory T cells (Treg), however the mechanism for this is unknown. Here we show that an oncolytic strain of vaccinia virus (VV) infects tumor infiltrating Tregs, in contrast to the prevailing idea that oncolytic viruses only infect tumor cells. Infection leads to viral-mediated Treg depletion that is required for tumor regression. Methods Using a mouse model of head and neck squamous cell carcinoma (MEER), a VV-resistant line was generated through serial treatment of a VV-sensitive MEER line. At varied time points post-intratumoral treatment with VV, tumor infiltrating lymphocytes (TIL) were isolated from both the VV-resistant and VV-sensitive lines and analyzed by flow cytometry. Results One day post-treatment of VV-sensitive MEER tumors, tumor isolated Tregs were infected by VV as determined by viral GFP expression. Infection was confirmed in vitro with purified Tregs. Four days post-treatment, tumor infiltrating Treg counts were reduced, and active caspase 3 staining was increased, suggesting that infection lead to Treg death. At 7 days post-treatment, the remaining Tregs in the VV-sensitive tumors acquired a fragile phenotype (IFN?+ Nrp1-). This was not observed in the VV-resistant MEER line. Fragile Tregs are less suppressive and indeed we observed an increase in pro-inflammatory cytokine production from CD8+ and Tconv (CD4+ Foxp3-) T cells in the VV-sensitive tumors compared to VV-resistant. We then engineered oncolytic VV to be susceptible to Cre mediated inactivation. Infection of various murine transgenic Cre lines confirmed the importance of non-tumoral immune infection for therapeutic efficacy, with a particular emphasis on Treg infection. Conclusions These data reveal a previously unappreciated mechanism of action of oncolytic virus immunotherapy, in which new tumor immunity accompanies the viral mediated loss and phenotypic change of regulatory populations. Importantly, as this treatment is delivered intratumorally the loss of Tregs is tumor specific, resulting in targeted Treg deletion without systemic autoimmunity.

Vesicular stomatitis virus sensitizes immunologically cold tumors to checkpoint blockade by inducing pyroptosis

Oncolytic Parapoxvirus induces Gasdermin E-mediated pyroptosis and activates antitumor immunity

Modulation of the tumor microenvironment by armed vesicular stomatitis virus in a syngeneic pancreatic cancer model

A novel vesicular stomatitis virus armed with IL-2 mimic for oncolytic therapy

RIG-I-mediated innate immune signaling in tumors reduces the therapeutic effect of oncolytic vesicular stomatitis virus

Overexpression of Smac by an Armed Vesicular Stomatitis Virus Overcomes Tumor Resistance

Tumor targeted inflammation and coagulation following oncolytic virus therapy compromises blood flow and triggers apoptosis of uninfected tumor cells

Efficacy and Safety of Oncolytic Virus Immunotherapy in Advanced Malignancies: A Systematic Review of 161 Clinical Studies

589 Efficacy of oncolytic vaccinia virus requires infection of suppressive immune cells in the tumor microenvironment leading to their reprogramming and deletion

A Dual‐Responsive STAT3 Inhibitor Nanoprodrug Combined with Oncolytic Virus Elicits Synergistic Antitumor Immune Responses by Igniting Pyroptosis

Dual‐Responsive STAT3 Inhibitor Nanoprodrug Combined with Oncolytic Virus Elicits Synergistic Antitumor Immune Responses by Igniting Pyroptosis

Intratumoral Delivery Of A Pd-1-Blocking Scfv Encoded In Oncolytic Hsv-1 Promotes Antitumor Immunity And Synergizes With Tigit Blockade

Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response

SARS-CoV-2 and oncolytic EV-D68-encoded proteases differentially regulate pyroptosis

An Oncolytic HSV-1 Armed with Visfatin Enhances Antitumor Effects by Remodeling Tumor Microenvironment Against Murine Pancreatic Cancer

Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer

Tumor-targeting oncolytic virus elicits potent immunotherapeutic vaccine responses to tumor antigens.

An Engineered Oncolytic Vaccinia Virus Encoding a Single-Chain Variable Fragment Against TIGIT Induces Effective Antitumor Immunity and Synergizes with PD-1 or LAG-3 Blockade.

Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia

Treatment with oncolytic vaccinia virus infects tumor-infiltrating regulatory and exhausted T cells

The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer